| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLAMF6 |
| Uniprot No | Q96DU3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-225aa |
| 氨基酸序列 | QSSLTPLMVNGILGESVTLPLEFPAGEKVNFITWLFNETSLAFIVPHETK SPEIHVTNPKQGKRLNFTQSYSLQLSNLKMEDTGSYRAQISTKTSAKLSS YTLRILRQLRNIQVTNHSQLFQNMTCELHLTCSVEDADDNVSFRWEALGN TLSSQPNLTVSWDPRISSEQDYTCIAENAVSNLSFSVSAQKLCEDVKIQY TDTKVDHHHHHH |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLAMF6重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**: "Structural and functional characterization of recombinant SLAMF6 highlights its role in NK cell activation"
**作者**: Müller, H., et al.
**摘要**: 该研究通过重组表达纯化SLAMF6蛋白，解析其晶体结构，发现其胞外域独特的免疫球蛋白样折叠特征，并验证其在自然杀伤(NK)细胞活化中的共刺激作用，为靶向SLAMF6的免疫治疗提供结构基础。
---
2. **文献名称**: "SLAMF6 regulates T cell exhaustion via interaction with the inhibitory receptor CD226"
**作者**: Li, Y., et al.
**摘要**: 研究团队利用重组SLAMF6蛋白进行体外结合实验，证实其与CD226的相互作用可调控T细胞耗竭表型，阻断该通路可增强抗肿瘤免疫反应，提示重组SLAMF6在癌症免疫治疗中的潜在应用价值。
---
3. **文献名称**: "Recombinant SLAMF6 fusion protein enhances antitumor immunity by disrupting immune checkpoint networks"
**作者**: Chen, X., et al.
**摘要**: 开发了一种重组SLAMF6-Fc融合蛋白，通过体外和小鼠模型实验证明其能有效阻断PD-1/PD-L1及CTLA-4通路，显著增强CD8+ T细胞活性，为多靶点免疫检查点抑制剂的开发提供了新策略。
---
注：上述文献为示例性内容，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of SLAMF6 Recombinant Protein**
SLAMF6 (Signaling Lymphocytic Activation Molecule Family Member 6), also known as CD352 or NTB-A, is a cell-surface receptor belonging to the SLAM family of immunomodulatory receptors. These receptors are primarily expressed on hematopoietic cells, including T cells, natural killer (NK) cells, and B cells, and play critical roles in regulating immune cell activation, differentiation, and tolerance. SLAMF6 features a conserved extracellular immunoglobulin (Ig)-like domain, a transmembrane region, and cytoplasmic tails containing immunoreceptor tyrosine-based switch motifs (ITSMs). These ITSMs recruit adaptor proteins like SAP (SLAM-associated protein) to mediate downstream signaling.
Functionally, SLAMF6 acts as a bidirectional regulator of immune responses. It facilitates cell-cell interactions by engaging homophilic or heterophilic ligands (e.g., SLAMF6-SLAMF6 or SLAMF6-SLAMF7 binding), modulating immune synapse formation. In T cells, SLAMF6 can either enhance activation or promote inhibitory signals depending on the cellular context and SAP availability. For instance, in NK cells, SLAMF6 collaborates with other receptors to fine-tune cytotoxicity and cytokine production. Dysregulation of SLAMF6 has been implicated in autoimmune diseases, viral infections, and cancer, highlighting its therapeutic potential.
Recombinant SLAMF6 protein is engineered *in vitro* to study its structural and functional properties. Typically produced in mammalian expression systems, it retains post-translational modifications and ligand-binding capabilities. Researchers utilize this protein to investigate receptor-ligand interactions, signaling mechanisms, and its role in immune regulation. Additionally, SLAMF6 recombinant proteins serve as tools for developing targeted therapies, such as checkpoint inhibitors or agonists, to modulate immune responses in diseases like cancer or chronic inflammation. Recent studies also explore SLAMF6 as a potential biomarker or co-target in combination with PD-1/PD-L1 blockade therapies. Its dual role in immunity makes SLAMF6 a compelling subject for both basic research and translational applications.
×
